Marinomed 
Marinomed Biotechnologie GmbH 创立于2006年，在一个创新的抗病毒呼吸技术平台基础上开发呼吸系统疾病的治疗药物。该技术的首个上市产品是一种抗病毒鼻腔喷雾剂，已证明该技术安全有效，具有实用性。Marinomed 在流感、抗哮喘药合剂和其他高危患者方面也有进一步的专攻产品，体现出该技术的巨大潜力。此外，该公司还开发一种针对I型变态反应和自身免疫疾病的新药。Marinomed Biotechnologie GmbH是从维也纳兽医大学分拆出来的公司，总部在奥地利维也纳。

Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments.

Marinomed has devoted its discovery and research efforts to the evolution of MAVIREX, a technology platform for the development of therapies that target more than 200 different respiratory virus strains based on polymers derived from red seaweed. The huge potential of this technology is reflected by Carragelose©, a unique broadly active anti-viral compound for treating respiratory diseases. Safety and antiviral effectiveness have been established in clinical trials involving both adults and children. The compound is approved for marketing in the EU as part of an anti-viral nasal spray targeting common cold.

Further novel anti-viral products derived from MAVIREX are currently being developed. These products comprise combinations with known compounds in the respiratory field, including influenza. Marinomed also develops products for at-risk patients for the prevention and treatment of respiratory virus infections that may cause a worsening of an underlying disease such as asthma, allergic rhinitis and COPD.

In addition, the Company develops novel treatments against Type I allergy and autoimmune diseases.

Marinomed is located in Vienna, Austria and was founded in March 2006 as a spin-off from the Veterinary University of Vienna.